Advertisement M D Anderson Cancer Center selects Instem's Provantis preclinical software - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

M D Anderson Cancer Center selects Instem’s Provantis preclinical software

Instem, a provider of early drug development software solutions, has announced that the University of Texas M D Anderson Cancer Center has purchased Provantis 8 for its research facilities in central Texas.

To begin leveraging a key part of the system right away, M D Anderson deployed Provantis Pathology using Instem’s remote hosted online model, allowing pathologists to access the software over the Internet from any location.

From the time they plan a preclinical study and allocate the resources, right through to final report production, M D Anderson has automated their processes using the following integrated Provantis modules – toxicology resource planning, general toxicology, pathology, clinical pathology, protocol & report assembly, tables & statistics, labeling, and dispense.

Instem additionally provided project management, implementation, validation and training services to M D Anderson during the project.

Provantis is a fully integrated software system for single users and global organizations engaged in non-clinical evaluation studies. Orchestrating every facet of preclinical drug safety assessment, Provantis streamlines processes and workflows with straightforward, intuitive functionality for simple and complex studies within a good laboratory practice (GLP) or non-GLP environment, Instem said.